Protagonist Therapeutics is an international biotechnology company pursuing the discovery and development of disulfide rich peptides (DRPs) as well differentiated alternatives to antibodies, and also as new chemical entities (NCEs) against those targets and life threatening diseases for which suitable small molecule and/or biologic options are not available.

The Company has developed a proprietary drug discovery technology platform that enables us to identify DRP based hits and leads against almost any type of targets in a de novo manner. These DRP molecules are highly constrained and stable chemical entities that combine the beneficial features of monoclonal antibody (mAb) drugs with the desired properties of small molecule drugs. These properties include improved oral stability, reduced immunogenicity, favorable pharmacokinetics, improved distribution and tissue penetration, and delivery by injectable and/or oral routes. DRPs are ideal scaffolds for drug discovery & development as their rigid framework imparts favorable chemical and biological stability characteristics and retains the sequence flexibility which permits the introduction of new and diverse functionalities.